MedTrace Logo

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

NCT00728494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2015-07-28

Study results available
· View outcomes & findings →

Summary

Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not. All patients will receive PegIntron and Rebetol according to label.

Conditions

  • Hepatitis C, Chronic
  • Hepatitis C

Interventions

BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

Peginterferon alfa-2b will be administered according to the product's labeling.

DRUG

Rebetol (ribavirin; SCH 18908)

Ribavirin will be administered according to the product's labeling.

BEHAVIORAL

Patient Assistance Program

The patient assistance program includes the following: * Training by physicians or specialized nurses. * Informational materials based on the "To beat HCV" program. * Management of specific side effects.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00728494 on ClinicalTrials.gov